Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT07677774
Recruiting Not applicable

GPC3-Targeted PET/CT in Hepatocellular Carcinoma

NCT07677774 · tracked via the Priya Life Science China tracker
Sponsor
The First Affiliated Hospital of Xiamen University
Phase
Not applicable
Started
2026-05-01
Last updated
2026-09-10

Condition(s) studied

Hepatocellular Carcinoma (HCC)Glypican-3GPC3-targeted PET/CT

Investigational drug(s) / intervention(s)

GPC3-targeted PET/CT

GPC3-targeted PET/CT: Participants will receive a single intravenous injection of 68Ga-GPC3, and undergo PET/CT imaging within the specified time.

Study summary

The objective of the study is to evaluate the diagnostic value of GPC3-targeted PET/CT in patients with suspected or histologically/clinically confirmed hepatocellular carcinoma, and to compare with contrast-enhanced MRI.

Eligibility

Sex
ALL
Min age
18 Years
Max age
90 Years
Healthy volunteers
No
Inclusion Criteria: * Adult patients (aged 18 years or older); * Patients with suspected, newly diagnosed, or previously treated hepatocellular carcinoma(supporting evidence may include imaging findings and pathology report); * Patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee. * Estimated life expectancy of more than 3 months, as assessed by the investigator, and ability to comply with study procedures and scheduled visits; Exclusion Criteria: * Lack of contrast-enhanced liver MRI or an interval of more than 14 days between GPC3-targeted PET/CT and contrast-enhanced liver MRI. * Receipt of antitumor treatment between imaging examinations. * The inability or unwillingness of the research participant or legal representative to provide written informed consent. * Inability to complete PET/CT imaging.

Primary outcome measure(s)

  • Diagnostic accuracy — 1 year
    The sensitivity, specificity, and accuracy of GPC3-targeted PET/CT and CE-MRI in detecting malignant hepatic lesions were calculated and compared.

Trial sites (1)

FacilityCityRegionStatus
The First Affiliated Hospital of Xiamen University Xiamen Fujian Recruiting

More The First Affiliated Hospital of Xiamen University trials in China

Trophoblast Cell-Surface Antigen 2 (Trop-2) Targeted PET/CT in Recurrent and Metastatic Thyroid Cancer Recruiting
Tofacitinib for Glucocorticoid-Resistant Moderate-to-Severe Thyroid Eye Disease Recruiting
Prospective Clinical Study of Orelabrutinib in Combination With Rituximab (OR) for Primary Marginal Zone Lymphoma (MZL) That Failed or Not Suitable for Local Therapy Recruiting
Effective Dose and Safety of Esketamine During Ultrasound-guided Hepatic Tumor Thermal Ablation Active, not recruiting
Lenalidomide Combined With G-CHOP in the Treatment of Newly Diagnosed DLBCL With FL Recruiting

Other trials for the same condition

HAIC Combined With Sintilimab Plus Bevacizumab Biosimilar for Advanced Hepatocellular Carcinoma (TASK-03) Recruiting
FAD Subtype-Guided Combination Therapy for Unresectable Hepatocellular Carcinoma Starting soon
Ultra-stable Iodized Oil-Chemo Embolization Seq Thermal Ablation in Early Liver Ca Active, not recruiting
Irreversible Electroporation Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular Carcinoma Recruiting
FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07677774 on ClinicalTrials.gov ↗ ← All trials in China